MAIA presents Phase 2 THIO-101 efficacy data in advanced NSCLC at ELCC 2025

MAIA Biotechnology, Inc.

Efficacy data from Phase 2 THIO-101 trial presented at European Lung Cancer Congress 2025 on March 28, 2025.
Trial evaluates THIO sequenced with cemiplimab in advanced NSCLC patients after 2+ prior therapies.
Poster copy filed as Exhibit 99.1 and posted on company website; no specific numeric results in 8-K text.
Data disclosure under Regulation FD; forward-looking statements caution against undue reliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.